Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
Matthew J. Frigault, Sarah Nikiforow, Michael K. Mansour, Zhen‐Huan Hu, Mary M. Horowitz, Marcie Riches, Peiman Hematti, Cameron J. Turtle, Mei-Jie Zhang, Miguel‐Angel Perales, Marcelo C. Pasquini
Topics & Concepts
TocilizumabCoronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PneumoniaBetacoronavirusVirologyInternal medicineImmunologyOutbreakDiseaseInfectious disease (medical specialty)CAR-T cell therapy researchCOVID-19 and healthcare impactsSARS-CoV-2 and COVID-19 Research